All In Biotech

Drug Trial Radar · NCT00648908

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial

Last checked: Nov 20, 2026Latest source record: Feb 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

269

Actual

Start

Jun 2006

Primary completion

Jan 2011

Study completion Apr 2011

Sponsor

Lead sponsor
Acorda TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 1, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who previously participated in Acorda Therapeutics Protocol MS-F203.

Conditions

  • Multiple Sclerosis

Interventions

  • Fampridine-SRDrug

    Tablets, 10 mg, BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of Treatment Emergent Adverse Events (TEAE).Time frame: up to 5 years

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • USC, Keck School of Medicine Health Care Consultation Center

    Los Angeles, California

  • UC Davis

    Sacramento, California

  • Shepherd Center

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Indiana University MS Center

    Indianapolis, Indiana

  • Maryland Center for MS

    Baltimore, Maryland

  • Wayne State University, Department of Neurology

    Detroit, Michigan

  • The Schapiro Center for MS

    Golden Valley, Minnesota

  • Washington University School of Medicine, Div. of Rehab/Neurology

    St Louis, Missouri

  • Advanced Neurology Specialists

    Great Falls, Montana

  • Gimbel MS Center at Holy Name Hospital

    Teaneck, New Jersey

  • Maimonides MS Care Center

    Brooklyn, New York

  • Corinne Goldsmith Dickinson Center for MS

    New York, New York

  • University of Rochester

    Rochester, New York

  • SUNY Stony Brook

    Stony Brook, New York

  • CMC - Neuroscience & Spine Institute, Division of Neurology

    Charlotte, North Carolina

  • Raleigh Neurology Associates

    Raleigh, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Ohio State University MS Center

    Columbus, Ohio

  • Oregon Health & Science University, MS Center of Oregon, UHS-42

    Portland, Oregon

  • Thomas Jefferson University Physicians

    Philadelphia, Pennsylvania

  • Allegheny General Hospital, Allegheny Neurological Associates

    Pittsburgh, Pennsylvania

  • University of Texas-Houston

    Houston, Texas

  • Neurological Research Center, Inc.

    Bennington, Vermont

  • Fletcher Allen Health Care

    Burlington, Vermont

  • MS Center at Evergreen

    Kirkland, Washington

  • Foothills Medical Center

    Calgary, Alberta, Canada

  • University of British Columbia, Vancouver Coastal Health Research Institute

    Vancouver, British Columbia, Canada

  • River Valley Health c/o Stan Cassidy Centre for Rehabilitation

    Fredericton, New Brunswick, Canada

  • QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site

    Halifax, Nova Scotia, Canada

  • Ottawa Hospital General Campus

    Ottawa, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.